S-Allyl cysteine attenuates free fatty acid-induced lipogenesis in human HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway

Journal of Nutritional Biochemistry

Volumn 24, Issue 8, 2013, Pages 1469-1478

  Hwang, Yong Pil ^a,b   Kim, Hyung Gyun ^a   Choi, Jae Ho ^a   Do, Minh Truong ^a   Chung, Young Chul ^b   Jeong, Tae Cheon ^c   Jeong, Hye Gwang ^a  

^a Chungnam National University   (South Korea)

^b International University of Korea   (South Korea)

^c Yeungnam University   (South Korea)

Author keywords

AMPK; Lipogenesis; Nonalcoholic fatty liver disease; S Allyl cysteine; Steatosis

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ALLYL CYSTEINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CASPASE 3; CASPASE 9; CHOLESTEROL; CYSTEINE DERIVATIVE; FAS ANTIGEN; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; REACTIVE OXYGEN METABOLITE; SILENT INFORMATION REGULATOR PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; LIPID STORAGE; LIPOGENESIS; LIPOTOXICITY; LIVER CELL DAMAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

3-HYDROXY-3-METHYLGLUTARYL COA REDUCTASE; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE-1-Β-D-RIBOFURANOSIDE; AICAR; AMP-ACTIVATED PROTEIN KINASE; AMPK; CALCIUM/CALMODULIN-DEPENDENT KINASE KINASE; CAMKK; FAS; FATTY ACID SYNTHASE; FFA; FREE FATTY ACID; HMGCR; LIPOGENESIS; NAFLD; NONALCOHOLIC FATTY LIVER DISEASE; REACTIVE OXYGEN SPECIES; ROS; S-ALLYL CYSTEINE; SAC; SREBP-1; STEATOSIS; STEROL REGULATORY ELEMENT BINDING PROTEIN-1; TG; TRIGLYCERIDE;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CASPASE 3; CASPASE 9; CELL SURVIVAL; CYSTEINE; DOWN-REGULATION; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GARLIC; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPOGENESIS; PHOSPHORYLATION; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ALLIUM SATIVUM;

EID: 84892440773     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.12.006     Document Type: Article

References (47)

1. Schreuder T.C., Verwer B.J., van Nieuwkerk C.M., Mulder C.J. Nonalcoholic fatty liver disease: an overview of current in- sights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008, 14:2474-2486.
2. Kotronen A., Yki-Jar̈rvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
3. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-152.
4. Marra F., Gastaldelli A., Svegliati Baroni G., Tell G., Tiribelli C. Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis. Trends Mol Med 2008, 14:72-81.
5. Parekh S., Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007, 132:2191-2207.
6. Malhi H., Bronk S.F., Werneburg N.W., Gores G.J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006, 281:12093-12101.
7. Feldstein A.E., Werneburg N.W., Canbay A., Guicciardi M.E., Bronk S.F., Rydzewski R., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
8. Rawson R.B. Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem Soc Symp 2003, 70:221-231.
9. Liang G., Yang J., Horton J.D., Hammer R.E., Goldstein J.L., Brown M.S. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem 2002, 277:9520-9528.
10. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., et al. Regulation of mouse sterol regulatory elementbinding protein-1c gene (SREBP-1c) by oxysterol receptors. LXRalpha and LXRbeta. Genes Dev 2000, 14:2819-2830.
11. Lage R., Dieguez C., Vidal-Puig A., Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 2008, 14:539-549.
12. Viollet B., Mounier R., Leclerc J., Yazigi A., Foretz M., Andreelli F. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 2007, 33:395-402.
13. Kefas B.A., Cai Y., Kerckhofs K., Ling Z., Martens G., Heimberg H., et al. Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol 2004, 68:409-416.
14. Kukidome D., Nishikawa T., Sonoda K., Imoto K., Fujisawa K., Yano M., et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006, 55:120-127.
15. Ota K., Nakamura J., Li W., Kozakae M., Watarai A., Nakamura N., et al. Metformin prevents methylglyoxal-induced apoptosis of mouse Schwann cells. Biochem Biophys Res Commun 2007, 357:270-275.
16. Ibrahim S.H., Kohli R., Gores G.J. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011, 53:131-140.
17. Geng Z., Rong Y., Lau B.H. S-Allyl cysteine inhibits activation of nuclear factor kappa B in human T cells. Free Radic Biol Med 1997, 23:345-350.
18. Kim J.M., Lee J.C., Chang N., Chun H.S., Kim W.K. S-Allyl-l-cysteine attenuates cerebral ischemic injury by scavenging peroxynitrite and inhibiting the activity of extracellular signal-regulated kinase. Free Radic Res 2006, 40:827-835.
19. Numagami Y., Ohnishi S.T. S-Allylcysteine inhibits free radical production, lipid peroxidation and neuronal damage in rat brain ischemia. J Nutr 2001, 131:1100S-1105S.
20. Saravanan G., Ponmurugan P., Senthil Kumar G.P., Rajarajan T. Antidiabetic properties of S-allylcysteine, a garlic component on streptozotocin-induced diabetes in rats. J Appl Biomed 2009, 7:151-159.
21. Saravanan G., Ponmurugan P., Senthil Kumar G.P., Rajarajan T. Modulatory effect of S-allylcysteine on glucose metabolism in streptozotocin induced diabetic rats. J Funct Foods 2009, 1:336-340.
22. Saravanan G., Ponmurugan P., Senthil Kumar G.P., Rajarajan T. Antidiabetic effect of S-allylcysteine: effect on plasma and tissue glycoproteins in experimental diabetes. Phytomedicine 2010, 17:1086-1089.
23. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
24. Zang M., Zuccollo A., Hou X., Nagata D., Walsh K., Herscovitz H., et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004, 279:47898-47905.
25. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
26. Lee M., Hwang J.T., Lee H.J., Jung S.N., Kang I., Chi S.G., et al. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 2003, 278:39653-39661.
27. Feldstein A.E., Werneburg N.W., Canbay A., Guicciardi M.E., Bronk S.F., Rydzewski R., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2000, 40:185-194.
28. Nehra V., Angulo P., Buchman A.L., Lindor K.D. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 2001, 46:2347-2352.
29. Hsu C.L., Yen G.C. Phenolic compounds: evidence for inhibitory effects against obesity and their underlying molecular signaling mechanisms. Mol Nutr Food Res 2008, 52:53-61.
30. de Vries J.E., Vork M.M., Roemen T.H., de Jong Y.F., Cleutjens J.P., van der Vusse G.J., et al. Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes. J Lipid Res 1997, 38:1384-1394.
31. Kalayarasan S., Sriram N., Sureshkumar A., Sudhandiran G. Chromium (VI)-induced oxidative stress and apoptosis is reduced by garlic and its derivative S-allylcysteine through the activation of Nrf2 in the hepatocytes of Wistar rats. J Appl Toxicol 2008, 28:908-919.
32. Araya J., Rodrigo R., Videla L.A., Thielemann L., Orellana M., Pettinelli P., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
33. Saravanan G., Ponmurugan P. Ameliorative potential of S-allyl cysteine on oxidative stress in STZ induced diabetic rats. Chem Biol Interact 2011, 189:100-106.
34. Hardie D.G. AMP-activated protein kinase: a master switch in glucose and lipid metabolism. Rev Endocr Metab Disord 2004, 5:119-125.
35. Park S.H., Gammon S.R., Knippers J.D., Paulsen S.R., Rubink D.S., Winder W.W. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol 2002, 92:2475-2482.
36. Ruderman N., Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004, 3:340-351.
37. Mao J., DeMayo F.J., Li H., Abu-Elheiga L., Gu Z., Shaikenov T.E., et al. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci U S A 2006, 103:8552-8557.
38. Abu-Elheiga L., Matzuk M.M., Abo-Hashema K.A., Wakil S.J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001, 291:2613-2616.
39. Musso G., Gambino R., Cassader M. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med 2010, 61:375-392.
40. Kohjima M., Higuchi N., Kato M., Kotoh K., Yoshimoto T., Fujino T., et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008, 21:507-511.
41. Park K.G., Min A.K., Koh E.H., Kim H.S., Kim M.O., Park H.S., et al. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology 2008, 48:1477-1486.
42. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
43. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
44. Hou X., Xu S., Maitland-Toolan K.A., Sato K., Jiang B., Ido Y., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008, 283:20015-20026.
45. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003, 115:42S-48S.
46. Pedraza-Chaverrí J., Medina-Campos O.N., Segoviano-Murillo S. Effect of heating on peroxynitrite scavenging capacity of garlic. Food Chem Toxicol 2007, 45:622-627.
47. Yates M.S., Tran Q.T., Dolan P.M., Osburn W.O., Shin S., McCulloch C.C., et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 2009, 30:1024-1031.